As in thyroid cancers, NRG1-induced HER3 activation plays an important role in adaptive resistance to RAF or MEK inhibitors in melanomas [55, 56], whereas EGFR plays a more critical role in colorectal cancers [3, 57]. This evidence concerns the gene EGFR and thyroid gland carcinoma.